↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Valensi P) "

Search: WFRF:(Valensi P)

Result 1-10 of 12

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Ryden, L, et al. (author) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary 2014 In: Diabetes & vascular disease research. - : SAGE Publications. - 1752-8984 .- 1479-1641. ; 11:3, s. 133-173 Journal article (peer-reviewed)
2.	Cosentino, F, et al. (author) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD 2020 In: European heart journal. - : Oxford University Press (OUP). - 1522-9645 .- 0195-668X. ; 41:2, s. 255-323 Journal article (peer-reviewed)
3.	Ibrahim, M, et al. (author) Cardio-renal-metabolic disease in primary care setting 2024 In: Diabetes/metabolism research and reviews. - 1520-7560. ; 40:3, s. e3755- Journal article (peer-reviewed)
4.	Cosentino, F, et al. (author) Clinical Practice Guides ESC 2019 guide on diabetes, prediabetes and cardiovascular disease, in collaboration with the European Association for the Study of Diabetes (EASD) 2020 In: REVISTA ESPANOLA DE CARDIOLOGIA. - : Elsevier BV. - 1885-5857 .- 0300-8932. ; 73:5 Journal article (other academic/artistic)
5.	Kopelman, P, et al. (author) Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients 2007 In: International journal of obesity (2005). - : Springer Science and Business Media LLC. - 0307-0565 .- 1476-5497. ; 31:3, s. 494-499 Journal article (peer-reviewed)
6.	Ryden, L, et al. (author) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) 2013 In: European heart journal. - : Oxford University Press (OUP). - 1522-9645 .- 0195-668X. ; 34:39, s. 3035- Journal article (peer-reviewed)
7.	Ryden, L, et al. (author) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (vol 34, pg 3035, 2013) 2014 In: EUROPEAN HEART JOURNAL. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 35:27, s. 1824-1824 Journal article (other academic/artistic)
8.	Ryden, L, et al. (author) [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD] 2013 In: Kardiologia polska. - 1897-4279. ; 7171 Suppl 11, s. S319-S394 Journal article (peer-reviewed)
9.	Aguiar, C, et al. (author) A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy 2015 In: Atherosclerosis. Supplements. - 1878-5050. ; 19, s. 1-12 Journal article (peer-reviewed)
10.	Ceriello, A, et al. (author) Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management 2021 In: Cardiovascular diabetology. - : Springer Science and Business Media LLC. - 1475-2840. ; 20:1, s. 218- Journal article (peer-reviewed)abstract Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of which is increasing worldwide. The aim of the review is to highlight the current perspectives of the pathophysiology of heart failure as it pertains to type 2 diabetes. This review summarizes the proposed mechanistic bases, explaining the myocardial damage induced by diabetes-related stressors and other risk factors, i.e., cardiomyopathy in type 2 diabetes. We highlight the complex pathology of individuals with type 2 diabetes, including the relationship with chronic kidney disease, metabolic alterations, and heart failure. We also discuss the current criteria used for heart failure diagnosis and the gold standard screening tools for individuals with type 2 diabetes. Currently approved pharmacological therapies with primary use in type 2 diabetes and heart failure, and the treatment-guiding role of NT-proBNP are also presented. Finally, the influence of the presence of type 2 diabetes as well as heart failure on COVID-19 severity is briefly discussed.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 12

Refine your search

Type of publication: journal article (12)

Type of content: peer-reviewed (10); other academic/artistic (2)

Author/Editor: Valensi, P (12); Cosentino, F (10); Marx, N (7); Rydén, L. (6); Zamorano, JL (6); Ceriello, A. (6); show more...; Huikuri, H (6); Tuomilehto, J. (5); Berne, C (4); Anker, SD (4); Seferovic, P (4); Tendera, M (4); Mellbin, L (4); Ostergren, J. (4); Seferovic, PM (4); Danchin, N (4); Taskinen, MR (4); Ferrari, R. (3); Sattar, N. (3); Reiner, Z (3); Viigimaa, M (3); JOHANSSON, I (2); Aboyans, V (2); Filippatos, G (2); Mueller, C. (2); Roffi, M (2); Piepoli, MF (2); Aguiar, C (2); Alegria, E (2); Bonadonna, RC (2); Catapano, AL (2); Elisaf, M (2); Farnier, M (2); Ferrieres, J (2); Filardi, PP (2); Hancu, N (2); Kayikcioglu, M (2); Silva, AME (2); Millan, J (2); Tokgozoglu, L (2); Vrablik, M (2); Zambon, A (2); Standl, E (2); Wijns, W (2); Schnell, O (2); Bueno, H (2); Delgado, V (2); Juni, P (2); Ostgren, CJ (2); Wheeler, DC (2); show less...

University: Karolinska Institutet (12); Uppsala University (1)

Language: English (12)

Research subject (UKÄ/SCB): Medical and Health Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view